These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 32533387)

  • 1. NMR quality control of fragment libraries for screening.
    Sreeramulu S; Richter C; Kuehn T; Azzaoui K; Blommers MJJ; Del Conte R; Fragai M; Trieloff N; Schmieder P; Nazaré M; Specker E; Ivanov V; Oschkinat H; Banci L; Schwalbe H
    J Biomol NMR; 2020 Nov; 74(10-11):555-563. PubMed ID: 32533387
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NMR-Fragment Based Virtual Screening: A Brief Overview.
    Singh M; Tam B; Akabayov B
    Molecules; 2018 Jan; 23(2):. PubMed ID: 29370102
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NMR-based Fragment Screening in a Minimum Sample but Maximum Automation Mode.
    Berg H; Wirtz Martin MA; Niesteruk A; Richter C; Sreeramulu S; Schwalbe H
    J Vis Exp; 2021 Jun; (172):. PubMed ID: 34152328
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Target immobilization as a strategy for NMR-based fragment screening: comparison of TINS, STD, and SPR for fragment hit identification.
    Kobayashi M; Retra K; Figaroa F; Hollander JG; Ab E; Heetebrij RJ; Irth H; Siegal G
    J Biomol Screen; 2010 Sep; 15(8):978-89. PubMed ID: 20817886
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design of a Fragment-Screening Library.
    Taylor A; Doak BC; Scanlon MJ
    Methods Enzymol; 2018; 610():97-115. PubMed ID: 30390807
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant Kinase Production and Fragment Screening by NMR Spectroscopy.
    Han B; Ahn HC
    Methods Mol Biol; 2016; 1360():35-46. PubMed ID: 26501900
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fragment-based screening by protein-detected NMR spectroscopy.
    Kerber PJ; Nuñez R; Jensen DR; Zhou AL; Peterson FC; Hill RB; Volkman BF; Smith BC
    Methods Enzymol; 2023; 690():285-310. PubMed ID: 37858532
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development and Validation of 2D Difference Intensity Analysis for Chemical Library Screening by Protein-Detected NMR Spectroscopy.
    Egner JM; Jensen DR; Olp MD; Kennedy NW; Volkman BF; Peterson FC; Smith BC; Hill RB
    Chembiochem; 2018 Mar; 19(5):448-458. PubMed ID: 29239081
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NMR spectroscopy: the swiss army knife of drug discovery.
    Horst R; Farley KA; Kormos BL; Withka JM
    J Biomol NMR; 2020 Nov; 74(10-11):509-519. PubMed ID: 32617727
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advancing fragment binders to lead-like compounds using ligand and protein-based NMR spectroscopy.
    Maurer T
    Methods Enzymol; 2011; 493():469-85. PubMed ID: 21371602
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Revisiting biomolecular NMR spectroscopy for promoting small-molecule drug discovery.
    Hanzawa H; Shimada T; Takahashi M; Takahashi H
    J Biomol NMR; 2020 Nov; 74(10-11):501-508. PubMed ID: 32306215
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Practical aspects of NMR-based fragment screening.
    Lepre CA
    Methods Enzymol; 2011; 493():219-39. PubMed ID: 21371593
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mass spectrometry for fragment screening.
    Chan DS; Whitehouse AJ; Coyne AG; Abell C
    Essays Biochem; 2017 Nov; 61(5):465-473. PubMed ID: 28986384
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NMR fragment screening reveals a novel small molecule binding site near the catalytic surface of the disulfide-dithiol oxidoreductase enzyme DsbA from Burkholderia pseudomallei.
    Nebl S; Alwan WS; Williams ML; Sharma G; Taylor A; Doak BC; Wilde KL; McMahon RM; Halili MA; Martin JL; Capuano B; Fenwick RB; Mohanty B; Scanlon MJ
    J Biomol NMR; 2020 Nov; 74(10-11):595-611. PubMed ID: 32761504
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CcpNmr AnalysisScreen, a new software programme with dedicated automated analysis tools for fragment-based drug discovery by NMR.
    Mureddu LG; Ragan TJ; Brooksbank EJ; Vuister GW
    J Biomol NMR; 2020 Nov; 74(10-11):565-577. PubMed ID: 32638146
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NMR-based fragment screening and lead discovery accelerated by principal component analysis.
    Namanja AT; Xu J; Wu H; Sun Q; Upadhyay AK; Sun C; Van Doren SR; Petros AM
    J Biomol NMR; 2019 Dec; 73(12):675-685. PubMed ID: 31541395
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NMR in target driven drug discovery: why not?
    Keiffer S; Carneiro MG; Hollander J; Kobayashi M; Pogoryelev D; Ab E; Theisgen S; Müller G; Siegal G
    J Biomol NMR; 2020 Nov; 74(10-11):521-529. PubMed ID: 32901320
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Counting on Fragment Based Drug Design Approach for Drug Discovery.
    Kashyap A; Singh PK; Silakari O
    Curr Top Med Chem; 2018; 18(27):2284-2293. PubMed ID: 30499406
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The 3F Library: Fluorinated Fsp
    Troelsen NS; Shanina E; Gonzalez-Romero D; Danková D; Jensen ISA; Śniady KJ; Nami F; Zhang H; Rademacher C; Cuenda A; Gotfredsen CH; Clausen MH
    Angew Chem Int Ed Engl; 2020 Feb; 59(6):2204-2210. PubMed ID: 31724281
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NMR in structure-based drug design.
    Carneiro MG; Ab E; Theisgen S; Siegal G
    Essays Biochem; 2017 Nov; 61(5):485-493. PubMed ID: 29118095
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.